Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

1. Management of osteoporosis and the prevention of fragility fractures

Management of osteoporosis and the prevention of fragility fractures Management of osteoporosis and the prevention of fragility fractures A national clinical guideline First published March 2015 Revised edition published June 2020 SIGN142Key to evidence statements and recommendations Levels of evidence 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 – Meta (...) used by Scottish Intercollegiate Guidelines Network to produce clinical guidelines. The accreditation term is valid until 30 June 2020 and is applicable to guidance produced using the processes described in SIGN 50: a guideline developer’s handbook, 2019 edition (https://www.sign.ac.uk/assets/sign50_2019.pdf). More information on accreditation can be viewed at www.nice.org.uk/accreditationScottish Intercollegiate Guidelines Network Management of osteoporosis and the prevention of fragility

2020 SIGN

2. Physical fitness in older women with osteoporosis and vertebral fracture after a resistance and balance exercise programme: 3-month post-intervention follow-up of a randomised controlled trial Full Text available with Trip Pro

Physical fitness in older women with osteoporosis and vertebral fracture after a resistance and balance exercise programme: 3-month post-intervention follow-up of a randomised controlled trial Physical fitness in older women with osteoporosis and vertebral fracture after a resistance and balance exercise programme: 3-month post-intervention follow-up of a randomised controlled trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) Permalink Copy Page navigation BMC Musculoskelet Disord Actions . 2020 Jul 18;21(1):471. doi: 10.1186/s12891-020-03495-9. Physical fitness in older women with osteoporosis and vertebral fracture after a resistance and balance exercise programme: 3-month post-intervention follow-up of a randomised controlled trial , , , , , Affiliations Expand Affiliations 1 Institute of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway. bsugland@oslomet.no. 2 Institute

2020 EvidenceUpdates

3. AACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis

AACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis ENDOCRINE PRACTICE Vol 26 (Suppl 1) May 2020 1 Copyright © 2020 AACE Clinical Practice Guidelines AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/ AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS— 2020 UPDATE Pauline M. Camacho, MD, FACE 1 ; Steven M. Petak, MD, JD, FACP , FCLM, MACE, CCD 2 ; Neil Binkley, MD 3 ; Dima L (...) , 2020 From the 1 Guideline Task Force Co-Chair, Professor of Medicine, Director, Loyola University Osteoporosis and Metabolic Bone Disease Center, Maywood, Illinois, 2 Guideline Task Force Co-Chair, Associate Clinical Professor, Weill-Cornell Medical College, Division Head and Service Chief, Endocrinology, Houston Methodist Hospital, Charles and Anne Duncan Centennial Clinical Academic Scholar in Endocrinology, Houston, Texas, 3 Professor of Medicine, Divisions of Endocrinology and Geriatrics

2020 American Association of Clinical Endocrinologists

4. Teriparatide (Osnuvo) - osteoporosis

Teriparatide (Osnuvo) - osteoporosis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2020 Health Canada - Drug and Health Product Register

5. Denosumab (Prolia) and steroid-induced osteoporosis

Denosumab (Prolia) and steroid-induced osteoporosis Prescrire IN ENGLISH - Spotlight ''Denosumab (Prolia°) and steroid-induced osteoporosis'', 1 April 2020 {1} {1} {1} | | > > > Denosumab (Prolia°) and steroid-induced osteoporosis Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the April issue of Prescrire International: Denosumab (Prolia (...) °) and steroid-induced osteoporosis FREE DOWNLOAD Denosumab (Prolia°) has an unfavourable harm-benefit balance in the prevention of osteoporotic fractures. It has also been authorised in the prevention of osteoporosis induced by prolonged corticosteroid therapy. How do Prescrire's editors rate denosumab in this situation? Full text available for free download. Prescrire's rating NOT ACCEPTABLE Denosumab has not been shown to prevent clinical fractures, but it has many adverse effects that can be severe

2020 Prescrire

6. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update Full Text available with Trip Pro

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic ') We use cookies to enhance your experience on our website.By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Navbar Search Filter Mobile (...) Microsite Search Term search filter search input Article Navigation Close mobile search navigation Article Navigation March 2020 Article Contents Article Navigation Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update Dolores Shoback Endocrine Research Unit, San Francisco Veterans Affairs Medical Center, Department of Medicine , San Francisco, California Department of Medicine, University of California San Francisco , San Francisco, California Search

2020 The Endocrine Society

7. Osteoporosis - prevention of fragility fractures: Scenario: Management

Osteoporosis - prevention of fragility fractures: Scenario: Management Scenario: Management | Management | Osteoporosis - prevention of fragility fractures | CKS | NICE Search CKS… Menu Scenario: Management Osteoporosis - prevention of fragility fractures: Scenario: Management Last revised in 2016 Scenario: Management How should I manage fragility fracture risk scores? For people at high risk of fragility fracture For people whose fracture risk is above the recommended threshold, offer a dual (...) These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline Osteoporosis: assessing the risk of fragility fracture [ ] and the Scottish Intercollegiate Guidelines Network (SIGN) guideline Management of osteoporosis and the prevention of fragility fractures [ ]. What drug treatments are recommended for people at high risk of osteoporotic fracture? If bone-sparing treatment is recommended, prescribe a bisphosphonate (alendronate 10 mg once daily or 70 mg once weekly

2020 NICE Clinical Knowledge Summaries

8. Osteoporosis - prevention of fragility fractures: Scenario: Assessment

Osteoporosis - prevention of fragility fractures: Scenario: Assessment Scenario: Assessment | Management | Osteoporosis - prevention of fragility fractures | CKS | NICE Search CKS… Menu Scenario: Assessment Osteoporosis - prevention of fragility fractures: Scenario: Assessment Last revised in 2016 Scenario: Assessment Who should I assess for fragility fracture risk? Identify high-risk groups of people to assess fragility fracture risk. These groups should include: All women aged 65 years (...) and over, and all men aged 75 years and over. All women aged 50–64 years and all men aged 50–74 years who have any of the following risk factors: A previous osteoporotic fragility fracture. Current use or frequent recent use of oral corticosteroids. History of falls. Low body mass index (less than 18.5 kg/m 2 Smoker. Alcohol intake of more than 14 units per week. A secondary cause of osteoporosis, including: Hypogonadism in either sex, including untreated premature menopause (menopause before 40 years

2020 NICE Clinical Knowledge Summaries

9. Osteoporosis - prevention of fragility fractures: Calcium and colecalciferol (vitamin D3) preparations

Osteoporosis - prevention of fragility fractures: Calcium and colecalciferol (vitamin D3) preparations Calcium and colecalciferol (vitamin D3) preparations | Prescribing information | Osteoporosis - prevention of fragility fractures | CKS | NICE Search CKS… Menu Calcium and colecalciferol (vitamin D3) preparations Osteoporosis - prevention of fragility fractures: Calcium and colecalciferol (vitamin D3) preparations Last revised in 2016 Calcium and colecalciferol (vitamin D3) preparations What

2020 NICE Clinical Knowledge Summaries

10. Romosozumab (Evenity) - treatment of osteoporosis in postmenopausal women at high risk for fracture

Romosozumab (Evenity) - treatment of osteoporosis in postmenopausal women at high risk for fracture Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register

11. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study (Abstract)

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study Odanacatib, a cathepsin K inhibitor, reduces bone resorption while maintaining bone formation. Previous work has shown that odanacatib increases bone mineral density in postmenopausal women with low bone mass. We aimed to investigate the efficacy and safety of odanacatib to reduce fracture risk in postmenopausal women (...) , more than one vertebral fracture, or a T-score of less than -4·0 at the total hip or femoral neck were not eligible unless they were unable or unwilling to use approved osteoporosis treatment. Participants were randomly assigned (1:1) to either oral odanacatib (50 mg once per week) or matching placebo. Randomisation was done using an interactive voice recognition system after stratification for previous radiographic vertebral fracture, and treatment was masked to study participants, investigators

2019 EvidenceUpdates

12. Romosozymab (Evenity) - Osteoporosis

Romosozymab (Evenity) - Osteoporosis Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you are accessing

2019 Health Canada - drugs and medical devices

13. Diagnosis of osteoporosis in statin-treated patients is dose-dependent Full Text available with Trip Pro

Diagnosis of osteoporosis in statin-treated patients is dose-dependent Whether HMG-CoA-reductase inhibition, the main mechanism of statins, plays a role in the pathogenesis of osteoporosis, is not entirely known so far. Consequently, this study was set out to investigate the relationship of different kinds and dosages of statins with osteoporosis, hypothesising that the inhibition of the synthesis of cholesterol could influence sex-hormones and therefore the diagnosis of osteoporosis.Medical (...) claims data of all Austrians from 2006 to 2007 was used to identify all patients treated with statins to compute their daily defined dose averages of six different types of statins. We applied multiple logistic regression to analyse the dose-dependent risks of being diagnosed with osteoporosis for each statin individually.In the general study population, statin treatment was associated with an overrepresentation of diagnosed osteoporosis compared with controls (OR: 3.62, 95% CI 3.55 to 3.69, p<0.01

2019 EvidenceUpdates

14. Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines

Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines | CADTH.ca Find the information you need Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Last updated: August 22, 2019 Project Number (...) : RA1059-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical evidence for varying treatment duration and courses of bisphosphonates for osteoporosis? What are the evidence-based guidelines regarding length of treatment with bisphosphonates for osteoporosis? Key Message One health technology assessment, six systematic reviews (one with meta-analyses), three randomized controlled trials, and five non-randomized studies were identified

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

15. Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women

Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women | CADTH.ca Find the information you need Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women Last updated: October 11, 2019 Project Number: HE0023-000 Product Line: Technology Review Research Type: Drug Result type: Report Expected (...) Completion Date: December 20, 2019 Osteoporosis is a systemic skeletal disease characterized by a loss of bone mass and an increased risk of fragility fractures. Osteoporosis is highly prevalent, affecting an estimated 1.5 million Canadians over 40 years of age. Fractures associated with osteoporosis commonly occur in vertebral sites, but also occur in non-vertebral sites. They are associated with significant costs, diminished quality of life, and mortality, as well as an increased risk of future

2019 CADTH - Technology Review

16. Pharmacological Management of Osteoporosis in Postmenopausal Women Full Text available with Trip Pro

Pharmacological Management of Osteoporosis in Postmenopausal Women We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite (...) Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation May 2019 Article Contents Article Navigation Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline Richard Eastell University of Sheffield, Sheffield, United Kingdom Search for other works by this author on: Clifford J Rosen Maine Medical Center Research Institute, Scarborough, Maine Correspondence: Clifford J. Rosen, MD

2019 The Endocrine Society

17. What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it?

What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it? Chiefs’ Inquiry Corner August 5th, 2019 – Clinical Correlations Search Chiefs’ Inquiry Corner August 5th, 2019 August 5, 2019 2 min read Patients with chronic liver disease are nearly three times more likely to develop osteoporosis than matched controls. In contrast to patients with post-menopausal osteoporosis, in whom increased osteoclast activity depletes bone density, the mechanism

2019 Clinical Correlations

18. Romosozumab aqqg (Evenity) - To treat osteoporosis in postmenopausal women at high risk of fracture

Romosozumab aqqg (Evenity) - To treat osteoporosis in postmenopausal women at high risk of fracture Drug Approval Package: Evenity U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Evenity Company: Amgen Inc. Application Number: 761062 Approval Date: 04/09/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2019 FDA - Drug Approval Package

19. Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Comparative Effectiveness Review Number 218 RComparative Effectiveness Review Number 218 Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 (...) . Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19-EHC016-EF April 2019 ii Key Messages Purpose of Review To summarize the effects of long-term osteoporosis drug treatment and of osteoporosis drug treatment discontinuation and holidays. Key Messages • Evidence on the effects of long-term osteoporosis drug treatment and drug continuation versus discontinuation is mostly limited to white, healthy, postmenopausal women. • Long-term alendronate reduces radiographic vertebral and nonvertebral fractures

2019 Effective Health Care Program (AHRQ)

20. Osteoporosis. (Abstract)

Osteoporosis. Fractures resulting from osteoporosis become increasingly common in women after age 55 years and men after age 65 years, resulting in substantial bone-associated morbidities, and increased mortality and health-care costs. Research advances have led to a more accurate assessment of fracture risk and have increased the range of therapeutic options available to prevent fractures. Fracture risk algorithms that combine clinical risk factors and bone mineral density are now widely used (...) in clinical practice to target high-risk individuals for treatment. The discovery of key pathways regulating bone resorption and formation has identified new approaches to treatment with distinctive mechanisms of action. Osteoporosis is a chronic condition and long-term, sometimes lifelong, management is required. In individuals at high risk of fracture, the benefit versus risk profile is likely to be favourable for up to 10 years of treatment with bisphosphonates or denosumab. In people at a very high

2019 Lancet